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Background: LKB1 (also known as STK11; locus 19p13.3) is regarded 
as a causative gene of Peutz-Jeghers syndrome. Somatic mutations 
in the LKB1 gene are relatively rare in sporadic cancers, but they 
are reported to occur in 26% of lung adenocarcinomas in Caucasian 
patients and in 54% of lung adenocarcinoma cell lines. The aim of this 
study was to determine mutational frequency of the LKB1 gene and to 
investigate the expression levels of the LKB1 gene in Japanese patients 
with lung cancer.
Methods: We sequenced the LKB1 gene in 22 lung cancer cell lines 
(including eight adenocarcinomas, six squamous cell carcinomas, three 
large-cell carcinomas, and ﬁve small-cell carcinomas; eleven were of 
Japanese origin and the others were of Caucasian origin). One-hundred 
resected specimens (81 adenocarcinomas, 14 squamous cell carcino-
mas, and ﬁve other histological types) from Japanese patients with pri-
mary lung cancer were also analyzed. In addition, the expression levels 
of the LKB1 gene were determined by quantitative real-time reverse 
transcription-PCR and the results were correlated with the clinical and 
pathological features of patients including KRAS, TP53!, EGFR, and 
HER2 gene status.
Results: Among the 22 cell lines, four had LKB1 mutations. The 
mutations detected were Gln to stop at codon 37 (A549, NCI-H460), 
Trp to stop at codon 332 (H23), and a deletion of codons 465-97 
(VMRC-LCD). They were all Caucasian origin, and three of them were 
in adenocarcinoma. In 100 resected lung cancer specimens, only three 
patients had LKB1 somatic mutations (3%). One was a one-base dele-
tion mutation (842delC), and two were missense mutations (Pro to Leu 
at codon 281[P281L], and Trp to Leu at codon 308 [W308L]). W308L 
has not been reported previously. All patients with the LKB1 gene mu-
tation were male smokers with adenocarcinomas. Of these three cases, 
two had poorly differentiated tumors and one had well differentiated 
tumor. Two were stage IIIA and one was stage IB. These three patients 
each had another mutation in either of the EGFR, KRAS or TP53 gene. 
No signiﬁcant correlation was observed between the expression level of 
LKB1 and clinicopathological features.
Conclusions: LKB1 gene mutations appear to be relatively rare in 
Japanese patients with lung cancer compared with Caucasian patients. 
Tumors with LKB1 mutation seem to have high malignant potential. 
However LKB1 seems to play a minor role in the lung cancer of Japa-
nese patients, because of low tendency of LKB1 mutations in Japanese. 
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Background: Worldwide, lung cancer continues to be the leading 
cause of cancer death in both men and women. Tobacco smoking 
remains the single most important risk factor for development of lung 
cancer, especially in males. Cytochrome P450 1A (CYP1A) family has 
been shown to play an important role in the metabolic activation of the 
constituents of tobacco smoke and other polycyclic aromatic hydrocar-
bons (PAHs). CYP1A inducibility has been shown to be a susceptibility 
biomarker for lung cancer. Several studies have demonstrated an as-
sociation between CYP1A-dependent enzyme inducibility and tobacco 
induced lung cancer risk. As CYP1A1 has been shown to be expressed 
in blood lymphocytes, blood CYP1A proﬁle could be potential candi-
date for use as a biomarker to predict PAH induced toxicity including 
lung cancer. The present study attempted to utilize blood lymphocyte 
CYP1A1 expression proﬁles as a possible biomarker for lung can-
cer by studying the CYP1A1 mRNA expression and the activity of 
7-ethoxyresoruﬁn-O-deethylase (EROD) in the blood lymphocytes of 
patients suffering from lung cancer, prior to the treatment (chemo/ra-
diotherapy) and after the treatment during follow-up.
Methods: Lung cancer patients visiting OPD facility of Department of 
Radiotherapy of King George’s Medical University, Lucknow and age 
and sex matched controls were included in the study. Blood was drawn 
from the patients prior to the start of the treatment and after treatment 
(routine regimen of chemotherapy and radiotherapy) was completed. 
Blood was processed for the isolation of lymphocytes and the activ-
ity of EROD was assayed in the blood lymphocytes. Total RNA was 
extracted from whole blood with TRI-BD (Sigma-USA) according to 
manufacturer’s protocol and was analyzed for CYP1A1 mRNA by RT-
PCR analysis. 
Results: RT-PCR of RNA collected from blood lymphocytes isolated 
from controls and patients, after normalization with β-actin, an house 
keeping gene revealed signiﬁcant increase in the mRNA expression of 
CYP1A1 in the patients (103%) suffering from squamous cell carci-
noma of lung malignancy. The increase in blood lymphocyte CYP1A1 
mRNA was associated with signiﬁcant increase (179%) in the activ-
ity of EROD in blood lymphocytes isolated from patients suffering 
from lung cancer. After receiving standard dose of chemotherapy and 
radiotherapy, the increase in the blood lymphocyte CYP1A1 mRNA 
levels in the patients was found to decline (20% increase), though the 
CYP1A1 expression was found to be higher than the controls. Our data 
further revealed that associated with the increase in mRNA expres-
sion, a signiﬁcant increase in the activity of CYP1A-dependent EROD 
(179%) was observed in the blood lymphocytes of patients suffering 
from lung cancer. Treatment (chemotherapy and radiotherapy) resulted 
in the decline in the induced enzyme levels, though the activity re-
mained elevated (100%) when compared to the controls. 
Conclusion: Increase in the blood lymphocyte CYP1A1 levels in the 
lung cancer patients and a trend towards the decline in the induced 
mRNA levels of CYP1A1 following chemotherapy and radiotherapy 
